STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

Inclusion Criteria:

• Patients affected by acute anterior ST elevation myocardial infarction (STEMI)undergoing primary percutaneous coronary intervention (PCI) or PCI-rescue withpersistent occlusion of coronary artery,
• Time symptom-to-balloon (≥3 h and ≤12h or ≤24 h if symptoms persist),
• Thrombolysis in Myocardial Infarction (TIMI) flow post PCI ≥2,
• Evidence of left ventricular (LV) dysfunction (EF biplane ≤45%) ≤24 h afterrevascularization,
• Men and women aged ≥18 years and ≤75 years,
• Informed consent must be signed before proceeding with any study procedure.

Exclusion Criteria:

• Previous anterior MI,
• Recent MI (within 1 month),
• Known previous LV dysfunction (EF <45%),
• Patients with angiographic evidence of coronary anatomy not suitable for PCI, orneeding coronary artery bypass grafting (CABG),
• Valve disease requiring surgical correction,
• History of previous cardiac surgery or PCI on LAD within 6 months,
• Previous or current documented history of leukemia, myeloproliferative ormyelodysplastic disorder,
• Previous or current documented history of malignant disease,
• Haemoglobin <10 mg/dl,
• White blood cells (WBC) >25.000 mm3,
• Platelet <50.000 mm3,
• Sepsis,
• Known HIV infection,
• Immune system diseases,
• Interstitial lung disease
• Serious concomitant medical conditions (other than ischemic heart disease),
• Pregnancy and breast feeding,
• Documented alcohol and drug abuse,
• Anticipated poor compliance.
• Current participation in a clinical trial with other investigational products
• Other cell therapy.